Biological effects of thyrotropin receptor activation on human orbital preadipocytes.
OBJECTIVE
Thyrotropin receptor (TSHR) expression is upregulated in the orbits of patients with Graves ophthalmopathy (GO), most of whom have TSHR-stimulating antibodies. The authors investigated the biological effects of TSHR activation in vitro in adipose tissue, the site of orbital TSHR expression.


METHODS
Activating mutant TSHR (TSHR*) or wild-type (WT) was introduced into human orbital preadipocytes using retroviral vectors. Their proliferation (Coulter counting), basal cAMP accumulation (radioimmunoassay), and spontaneous and peroxisome proliferator-activated receptor (PPARgamma)-induced adipogenesis (quantitative oil red O staining) were assessed and compared with those of nonmodified cells. QRT-PCR was used to measure transcripts of CCAT/enhancer binding protein (C/EBP)beta, PPARgamma, and lipoprotein lipase (LPL; early, intermediate, and late markers of adipogenesis) and for uncoupling protein (UCP)-1 (brown adipose tissue [BAT]).


RESULTS
Expression of TSHR* significantly inhibited the proliferation of preadipocytes and produced an increase in unstimulated cAMP of 200% to 600%. Basal lipid levels were significantly increased in TSHR* (127%-275%) compared with nonmodified (100%) or WT-expressing (104%-187%) cells. This was accompanied by 2- to 10-fold increases in early-intermediate markers and UCP-1 transcripts (2- to 8-fold); LPL was at the limit of detection. In nonmodified cells, adipogenesis produced significant increases in transcripts of all markers, including LPL (approximately 30-fold). This was not the case in TSHR*-expressing cells, which also displayed 67% to 84% reductions in lipid levels.


CONCLUSIONS
TSHR activation stimulates early differentiation (favoring BAT formation?) but renders preadipocytes refractory to PPARgamma-induced adipogenesis. In neither case did lipid-containing vacuoles accumulate, suggesting that terminal stages of differentiation were inhibited.
Zhang
Lei
L
Centre for Endocrine and Diabetes Sciences, School of Medicine, Cardiff University, United Kingdom.
Baker
Glynn
G
Janus
Dominika
D
Paddon
Carol A
CA
Fuhrer
Dagmar
D
Ludgate
Marian
M
D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism*; D050156:Adipogenesis / Q000187:drug effects / Q000502:physiology*; D002001:Adipose Tissue, Brown / Q000378:metabolism; D049109:Cell Proliferation; D000242:Cyclic AMP / Q000378:metabolism; D005822:Genetic Vectors; D049970:Graves Ophthalmopathy / Q000378:metabolism*; D006801:Humans; D007473:Ion Channels / Q000235:genetics; D050356:Lipid Metabolism; D008071:Lipoprotein Lipase / Q000235:genetics; D024101:Mitochondrial Proteins / Q000235:genetics; D009915:Orbit / Q000378:metabolism; D047495:PPAR gamma / Q000235:genetics / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D011863:Radioimmunoassay; D011989:Receptors, Thyrotropin / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D050656:Transcription Factor AP-2 / Q000235:genetics; D000071256:Uncoupling Protein 1
D007473:Ion Channels; D024101:Mitochondrial Proteins; D047495:PPAR gamma; D012333:RNA, Messenger; D011989:Receptors, Thyrotropin; D050656:Transcription Factor AP-2; C000604371:UCP1 protein, human; D000071256:Uncoupling Protein 1; D000242:Cyclic AMP; D008071:Lipoprotein Lipase